Published in
Elsevier, The Lancet Oncology, 6(18), p. 732-742
DOI: 10.1016/s1470-2045(17)30312-1
Links
Tools
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Journal article published in 2017 by
Véronique Diéras,
David Miles,
Sunil Verma,
Mark Pegram,
Manfred Welslau,
José Baselga,
Ian E. Krop,
Kim Blackwell,
Silke Hoersch,
Jin Xu,
Marjorie Green,
Luca Gianni 
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 